India, Aug. 4 -- AbbVie Inc. (ABBV) announced on Tuesday that Canada's Drug Agency (CDA-AMC) has recommended public reimbursement of UBRELVY, for the acute treatment of migraine, with or without aura, in adults with a history of moderate to severe migraine attacks.
The recommendation was supported by data from the pivotal Phase 3 ACHIEVE I and ACHIEVE II trials, which evaluated UBRELVY's ability to achieve pain freedom, pain relief, and freedom from the patient's most bothersome migraine-associated symptom following treatment of an acute migraine attack.
The CDA-AMC recommendation was informed by input from Canadian clinicians and patient organizations, including Migraine Canada, Migraine Quebec and the Canadian Migraine Society.
UBRELVY...